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This review evaluated published data regarding the eﬀects of ghrelin on GI motility using the PubMed database for English articles
from 1999 to September 2009. Our strategy was to combine all available information from previous literature, in order to provide
a complete structured review on the prokinetic properties of exogenous ghrelin and its potential use for treatment of various
GI dysmotility ailments. We classiﬁed the literature into two major groups, depending on whether studies were done in health
or in disease. We sub-classiﬁed the studies into stomach, small intestinal and colon studies, and broke them down further into
studies done in vitro, in vivo (animals) and in humans. Further more, the reviewed studies were presented in a chronological
order to guide the readers across the scientiﬁc advances in the ﬁeld. The review shows evidences that ghrelin and its (receptor)
agonists possess a strong prokinetic potential to serve in the treatment of diabetic, neurogenic or idiopathic gastroparesis and
possibly, chemotherapy-associated dyspepsia, postoperative, septic or post-burn ileus, opiate-induced bowel dysfunction and
chronic idiopathic constipation. Further research is necessary to close the gap in knowledge about the eﬀect of ghrelin on the
human intestines in health and disease.
1.Introduction
Ghrelin is a 28-amino acid motilin-related peptide hormone
mainly secreted by the X/A-like enteroendocrine cells of the
oxyntic (parietal) mucosa of the gastric fundus. It is the
endogenous ligand for the growth-hormone secretagogue
receptor (GHS-R) 1a, recently discovered by two indepen-
dent research groups [1, 2]. The discovery of ghrelin bore
great importance in the scientiﬁc media for the following
reasons: (1) ghrelin is the only endogenous (natural) ligand
for the GHS-R, ever discovered; (2) ghrelin shares similar
structure with motilin, the so-long called “orphan peptide,”
based on its unique structure; (3) ghrelin is the ﬁrst known
case of a peptide hormone modiﬁed by a fatty acid, the
n-octanoic acid; a step necessary for ghrelin to exert its
eﬀects [1]; (4) ghrelin is a hunger hormone that stimulates
appetite, food intake and promotes weight gain, that is,
ghrelin antagonist would serve as a potential treatment
for obesity. In addition, ghrelin’s poly-faceted properties
include prokinetic and possible anti-inﬂammatory abilities.
Although there has been several excellent reviews published
recently on the prokinetic eﬀects on ghrelin, some were
brief [3, 4], or combined with motilin [5, 6], and some
were focused on the eﬀect of ghrelin on the interdigestive
motility[7],gastrointestinal[GI]disorders[8,9],oracertain
subset of disease [10]. In the current review, we oﬀer a
complete detailed review solely on the prokinetic eﬀects of
exogenous ghrelin on the stomach and intestines in health
and in disease.
2. Methods
This review evaluated published data regarding the proki-
netic properties of exogenous ghrelin using the PubMed
database for English articles from 1999 to September 2009.
Our strategy was to combine and distil all currently available
studies and reviews in order to provide an overview on
exogenous ghrelin and its prokinetic abilities along the
gut in health and disease. The search was performed by
combining the terms “ghrelin” with “prokinetic” or with
“gastrointestinal motility.” Clinical trials and review articles
were speciﬁcally identiﬁed, and their reference citation lists
were searched for additional publications not identiﬁed in
the database searches. We classiﬁed the literature into two
major groups, depending on whether studies were done
in health or in disease. We sub-classiﬁed the studies into2 International Journal of Peptides
stomach, small intestinal and colon, and broke them down
further into in vitro, in vivo (animals) and in humans.
The reviewed studies were presented in a chronological
order to guide the readers across the scientiﬁc advances in
the ﬁeld. We have combined all the available information
from previous literature, in order to provide a complete
review on the prokinetic properties of exogenous ghrelin
and its potential applications for the treatment of various
gastrointestinal (GI) dysmotility ailments.
3. Effects of Ghrelinon Gastric
Motility in Health
3.1. In Vitro Gastric Tissues in Health. In vitro studies dem-
onstrated the prokinetic potential of ghrelin or its (receptor)
agonists in enhancing gastric muscle contractility via activa-
tion of the growth hormone secretagogue receptor (GHS-
R) and direct neural stimulation of the enteric nervous
system (ENSs); an eﬀect involving the cholinergic and
tachykininergic pathways. Earliest studies were done in 2003
by Dass et al. on rodent gastric fundic circular muscle strips.
Ghrelin concentration dependently increased the amplitude
of cholinergic oﬀ-contractions at concentrations from 0.1
to 10μM. Ghrelin did not aﬀect the neurogenic electrical
ﬁeld stimulation (EFSs) induced contractions [11]. They
conﬁrmed their results in 2005 [12]. Only a year later,
were they able to prove that ghrelin increased the EFS-
induced contractions using a concentration of 1μM[ 13].
Fukuda et al. conﬁrmed this eﬀect on the antrum and body
longitudinal muscle strips using the same concentration
of 1μM[ 14]. Depoortere et al. showed that ghrelin and
ghrelin receptor synthetic peptide agonist, growth hormone
receptor peptide 6 (GHRP-6), enhanced oﬀ-contractions
on both the fundus and the antrum [15]. They went
further to report such eﬀects in the presence of Nω-Nitro-
L-arginine-methyl-ester-hydrochloride (L-NAME), to verify
the involvement of nitric oxide (NO) in the EFS-induced
relaxationon-response.GhrelinorGHRP-6alsoenhancedL-
NAME-inducedcontractions;aneﬀectthatwasreproducible
in mice [15, 16]. The same research group conﬁrmed the
involvementofGHS-Ringhrelin’sexcitatoryeﬀectongastric
muscle tissue either by direct identiﬁcation of the GHS-R
1a transcripts in the muscle strips, or by testing the eﬀect
of treatment with the synthetic nopeptide GHS-R agonist
(capromorelin) [15, 16]. In the same year, Levin et al. [17],
reported that ghrelin’s excitatory eﬀect on the gastric fundus
was blocked by the pretreatment with atropine, suggesting
the involvement of the cholinergic pathway. Such conclusion
was conﬁrmed a year later by Bassil et al. who showed the
involvement of the tachykininergic pathway, as well [13].
Recently, ghrelin’s excitatory eﬀects have also been reported
in the upper gut of birds [18, 19].
3.2. In Vivo—Animal Stomach in Health. In vivo studies
showed the role of ghrelin in the regulation of the migrat-
ing motor complex (MMC) in the fasting state and the
involvement of the activation of GHS-R and neuropeptide
Y (NPY) and possibly, vagal cholinergic neurons. In 2003,
Fujino et al. reported that IV ghrelin induced MMC in the
antrum of vagotomized fed rats via activation of the GHS-
R and NPY neurons [20]. In fact, ghrelin appears to be the
endogenous signal for the MMC in rodents [21]. In 2008,
Taniguchi et al. showed that ghrelin infusion increased the
motility index (MI) of antral phase III-like contractions,
dose dependently, in conscious freely moving rats [7]. A year
later, they conﬁrmed the same ﬁnding of increase MI in
conscious freely moving mice [22]. Zheng et al. reported that
ghrelin-induced phase III-like contractions in the antrum of
freely moving mice are mediated via the vagal cholinergic
pathway [23] .I nd o g s ,h o w e v e r ,g h r e l i nw a sr e p o rt e dt oh a v e
no eﬀect on MMCs, suggesting a possible species-related
variation [24]. Such variation may be related to the fact that
rodents do not express the motilin receptor, whereas in dog,
expressing ghrelin and motilin receptors, it is possible that
the endogenous signal for the MMC to be modulated by
motilin, with no response to ghrelin.
In vivo studies revealed opposite eﬀects of ghrelin on
the proximal and distal gastric tone in anaesthetized rats.
Kobashi et al. reported that ICV ghrelin, or direct injection
of ghrelin into the dorsal vagal complex (DVC), relaxed
the proximal stomach, while ICV ghrelin at a higher dose
contracted the distal stomach [25]. These results suggested
thepresenceofGHS-RintheDVC,aswellastheinvolvement
of vagal preganglionic neurons in the action of ghrelin on
gastric tone.
In vivo studies debated the eﬀect of ghrelin on gastric
myoelectrical activity (GMA). We have previously reported
no eﬀects of ghrelin on GMA in healthy dogs [26]a n d
have conﬁrmed it in rats (Sallam—unpublished). However,
T¨ umer et al. reported an enhancement of GMA following
ghrelin treatment using the same dose we used in rats
[27]. We tend to disagree that the reported enhancement
was substantial considering that it was within 5%–10%;
moreover, the rats had an almost 90% of normal slow waves
before the ghrelin treatment.
A number of in vivo studies preceded the in vitro studies
and demonstrated prokinetic eﬀects of ghrelin on gastric
motility exerted via a vagally mediated mechanism. Masuda
et al. were the ﬁrst to report that IV ghrelin enhanced
gastric contractions dose-dependently in anesthetized rats
(from 0.8, 4, and 20μg/kg) and the eﬀect was blocked by the
pretreatment with atropine or vagotomy [28]. Later, Trudel
et al. however, could not reproduce the results in anaes-
thetized rats; instead they performed the study in conscious
rats and reported that IV ghrelin dose-dependently (5 and
20μg/kg) accelerated gastric emptying [29]. A similar eﬀect
was reported with subcutaneous ghrelin (100nmol/Kg) in
conscious mice [30]. Fukuda et al. reported that IV ghrelin
(20μg/kg) accelerated gastric emptying of both nutrient and
non-nutrient meals in conscious rats. Pretreatment with
capsaicin blocked the eﬀect of ghrelin on only the nutrient
meal [14]. Using ghrelin infusion of 500pmol/Kg/min and
a similar gastric emptying assessment method, Levin et al.
could not reproduce Fukuda’s results regarding ghrelin’s
acceleration of the nutrient meal [17]. However, a number
of other studies conﬁrmed the ability of intravenous (IV) or
intraperitoneal (IP) ghrelin or ghrelin (receptor) agonists inInternational Journal of Peptides 3
Table 1: Prokinetic eﬀects of exogenous ghrelin on gastric motility in healthy human volunteers (D-Lys). GHRP-6: GHRP receptor
antagonist; GE: gastric emptying; GHRP-6: ghrelin secretagogue receptor 6 (non-synthetic ghrelin receptor agonist); GHS-R: growth
hormone secretagogue receptor; IV: intravenous; MI; motility index; MMC: migrating motor complex; SPECT: single photon emission
computed tomography; VAS: visual analogue scale.
Author Subjects Study design Ghrelin type Eﬀective dose Methods Results
Levin F.,
[39]
Healthy
volunteers
(5M, 3F)
Randomized,
double-blind,
placebo-
controlled,
crossover
Ghrelin 10pmol/Kg/min for
180min after meal
Assessment of solid
GE by scintigraphy
Ghrelin accelerated
the rate of GE
Tack J.,
[35]
Healthy fasting
volunteers
(4F, 5M)
Cross-sectional
Ghrelin
(Clinalfa,
Switzerland)
40μg IV infusion over
30min given 20min
after the end of phase
III of MMCs
Assessment of
antroduodenal
motility and gastric
tone by manometry
and barostat
Ghrelin induced
premature phase III
contractions and
increased the tone of
the proximal stomach
Cremonini F.,
[37]
Healthy
volunteers:
obese (5M, 20F)
and normal
weight (13F)
Randomized,
parallel-group, one
dose, double-blind,
placebo-controlled
Ghrelin
(Clinalfa,
Switzerland)
0.33μg/Kg IV given
10 minutes after IV
injection of
99mTc-pertechnetate
Assessment of gastric
volume and emptying
by SPECT
Assessment of
symptoms by VAS
Ghrelin marginally
decreased fasting
gastric volumes, but
not GE or symptoms
Bisschops R.,
[36]
Healthy
volunteers
(n = 9)
No information
(i) Ghrelin
(ii) GHRP-6
(Clinalfa,
Switzerland)
40μg IV infusion over
30min given 20min
after the end of phase
III of MMCs
Assessment of
antroduodenal
pressures by
manometry and
gastric tone by
barostat
(i) Ghrelin induced
phase III contractions
of gastric origin;
t h o s ew e r eo f
increased amplitude
and duration
(ii) Ghrelin increased
proximal gastric tone
Ang D.,
[38]
Healthy
volunteers
(4M, 6F)
Randomized,
placebo-
controlled,
double-blind,
cross over
Ghrelin
40μg IV infusion over
30min given10min
before meal
Assessment of gastric
accommodation by
barostat
(i) Ghrelin inhibited
gastric accommoda-
tion and decreased
postprandial gastric
volumes
(ii) Ghrelin had no
eﬀects on postpran-
dial symptoms
the acceleration of gastric emptying in rats [15, 27, 31, 32]
and mice [16, 32, 33], using a variety of methods for the
assessment of gastric emptying. Such results were equally
reproducible in ghrelin receptor knockout mice, suggesting
a minor role of ghrelin in gastric emptying regulation [34].
In dogs, ghrelin was reported to show no eﬀect on gastric
emptying in one study, but excitatory eﬀects on gastric
contractions in another [24, 26].
3.3. In Human—Stomach of Healthy Subjects. Studies on
the prokinetic eﬀects of exogenous ghrelin on the stomach
of healthy human volunteers are summarized in Table 1.
Researchers have been able to reproduce some of the in
vitro and in vivo results in healthy humans. The eﬀects of
ghrelin on the fasting, not fed, human stomach was similar
to in vivo studies. In fasted volunteers, ghrelin induced phase
III-like contractions [35]; an eﬀect that was conﬁrmed two
years later by Bisschops [36]. However, both research groups,
in addition to Cremonini et al. [37], reported that ghrelin
increased the tone of the proximal stomach in the fasting
state in healthy volunteers. Even postprandially, ghrelin
increased the tone of the proximal stomach [38]. Such
result is contradictory to an in vivo study in which ghrelin
decreased proximal stomach tone in rats [25]. However, it is
noteworthy that this particular in vivo study was performed
in anesthetized, not conscious animals.
In 2006, researchers debated the prokinetic eﬀect of
ghrelin on gastric emptying [37, 39]. It is possible that the
useofdiﬀerenttechniquesforassessmentofgastricemptying
might have been responsible for this discrepancy.
Ghrelin was reported to inhibit gastric accommoda-
tion in healthy volunteers [38]. This raises the question
of whether ghrelin would induce side eﬀects, similar to
erythromycin, the macrolide antibiotic and motilin recep-
tor agonist that inhibits postprandial accommodation and
induces postprandial symptoms. However, ghrelin has been
shown not to aﬀect meal related symptoms in healthy obese
or lean subjects [37, 38]. This is conceivable, as healthy
volunteers would not be expected to have pronounced
postprandial symptoms.4 International Journal of Peptides
4. Effects of Ghrelinon Gastric
MotilityinDisease
4.1. In Vitro Gastric Tissues in Disease. Two recent studies
by Qiu et al. reported that ghrelin or GHRP-6 increased the
amplitude of carbachol-induced contractions of the gastric
fundus of various diabetic rodent models [40, 41]. These
results were reproducible in vivo (see below).
4.2. In Vivo Gastric Motility in Animal Model of Diseases.
Studies on the prokinetic eﬀects of exogenous ghrelin on
diseased stomach in vivo are summarized in Table 2.A
number of studies have reported that ghrelin or GHRP-
6 accelerated or normalized gastric emptying in a variety
of diseased animal models; these include: diabetic, post-
operative, or morphine, or septic, or burn induced ileus,
and cisplatin induced dyspepsia models. (1) Diabetic model:
Qiu et al. published 3 papers in 2008 conﬁrming their
in vitro ﬁndings in two diabetic rodent models [40, 41,
47]. They also found that the excitatory eﬀects of ghrelin
or GHRP-6 on gastric emptying in diabetic gastroparesis
were mediated via the cholinergic pathway. (2) Postoperative
ileus and/or morphine-treated model: In 2002, Trudel et
al. showed that IV ghrelin (20μg/kg) normalized gastric
emptying in a postoperative ileus rat model [29]. A year
later, they conﬁrmed the same ﬁnding in dogs [42]. In 2005,
the same group reported that RC-1139, a ghrelin receptor
agonist, accelerated gastric emptying, dose-dependently, in
postoperative ileus or in healthy morphine-treated rodent
model. However, when postoperative ileus animals were
also given a dose of morphine, a higher dose of RC-1139
was needed to accelerate gastric emptying [31]. In 2007,
Venkova et al. tested another ghrelin receptor agonist, TZP-
101 and showed its ability to accelerate gastric emptying
in a postoperative ileus rodent model whether or not it
was aggravated by morphine [45]. (3) Septic model:i n
2004, De Winter et al. reported that IP ghrelin or GHRP-6
accelerated gastric emptying in a lipopolysaccharide (LPS)-
induced septic ileus rat model [33]. In 2009, Chen et al.
conﬁrmed that ghrelin accelerated gastric emptying in a LPS
septic ileus mouse model, but at a much lower dose [46]. (4)
Burn model: in 2007, we have reported the ability of ghrelin
to normalize gastric emptying in a 60% total body surface
area (TSBA) rat model; an eﬀect mediated by the cholinergic
pathway [44]. (5) Cisplatin-induced dyspepsia model: in 2006,
Liu et al [43]. reported that IP ghrelin improved gastric
emptying in a mouse model of dyspepsia.
4.3. In Human—Patients with Gastric Motility Disorders.
Studies on the prokinetic eﬀects of exogenous ghrelin in
dyspeptic and/or gastroparetic patients are summarized in
Table 3. From 2005 till present, most of the researchers
seem to agree that ghrelin can accelerate gastric emptying
in dyspeptic and/or gastroparetic patients. Unlike animal
studies, the eﬀects of ghrelin on gastric emptying in these
patients were irrespective to vagal contribution [49, 50],
giving hope to neuropathy gastroparetic patients. In 2009,
Ejskjaer et al. reported that TZP-101, the ghrelin receptor
agonist, also accelerated gastric emptying in diabetic patients
with gastroparesis [51].
Though the eﬀect of ghrelin on patients’ symptoms
remained debatable [36, 48, 49], TZP-101 was reported to
shownoeﬀectonthepostprandialsymptomsofdiabeticgas-
troparesis patients and its safety proﬁle has been determined
in a phase I trial [51, 52].
Despite the optimistic results of acute ghrelin admin-
istration on gastric motility in patients with gastroparesis,
many researchers showed their concern regarding the side
eﬀects of the chronic use of ghrelin. Being the ligand of
growth hormone secretagogue receptor, ghrelin has been
shown to induce growth hormone secretion [53] and insulin
resistance [54]; such eﬀects would cause serious unfavorable
side eﬀects in particular subsets of patients. Modiﬁcation of
ghrelin (receptor) agonists might be necessary to avoid such
problems. Long term studies will show whether the ghrelin
receptor would be desensitized by chronic activation, similar
to the motilin receptor. Treatment alteration between ghrelin
and motilin receptor agonists has been suggested [3]. The
new ghrelin receptor agonist, TZP-101, is promising as it
did not induce growth hormone secretion following either
peripheral or central administration [53]. TZP-101 has also
been claimed to have a lower tendency to provoke ghrelin
receptor desensitization [5, 52, 55].
5. Effects of GhrelinonIntestinal
Motility in Health
5.1. In Vitro—Intestinal Tissues in Health. In the small intes-
tine, studies reported a prokinetic eﬀect of ghrelin on jejunal
contractility in rodents, involving direct activation of the
GHS-R on the myenteric neurons and the cholinergic path-
way. In 2004, Fukuda et al. reported that ghrelin enhanced
EFS-induced contractions in longitudinal jejunal muscles
[14] and Edholm et al. reported that ghrelin enhanced
acetylcholine-induced contractions in circular jejunal mus-
cles; an eﬀect mediated via the cholinergic pathway [56]. In
2008, Bisschops proved that not only ghrelin, but GHRP-
6, dose-dependently activated the myenteric neurons by
eliciting a Ca2+ transient; this depended on direct activation
of the GHS-R [36].
In the colonic tissues, studies have shown that the
prokinetic eﬀects of ghrelin were species-speciﬁc. While it
induced colonic contractions in ﬁsh or birds [19, 57], ghrelin
had no eﬀect on the colon of rodents or humans [11, 12].
5.2. In Vivo—Intestinal Motility in Healthy Animals. In vivo
studies showed that ghrelin induced intestinal MMCs in
fed rats involving the activation of the cholinergic pathway,
and the NO, NPY or 5-hydroxytryptamine 4 (5-HT4)
receptors.In2003,Fujinoetal.reportedthatghrelininduced
MMCs in fed and/or vagotomized rats; this eﬀect was
blocked by immunoneutralization of the NPY receptor [20].
In 2004, Edholm reported that ghrelin dose-dependently
shortened the intestinal MMC cycles. Pretreatment with
atropine blocked the ghrelin eﬀect [56]. In 2007, Wang et al.
reproduced the exact same results in rats and showed thatInternational Journal of Peptides 5
Table 2: Prokinetic eﬀects of exogenous ghrelin on diseased stomach in vivo. GE: gastric emptying; GHRP-6: ghrelin secretagogue receptor
6 (non-synthetic ghrelin receptor agonist); h: hour; iNOS: inducible nitric oxide synthase; IP: intraperitoneal; IV: intravenous; L-NAME:
Nω-Nitro-L-arginine-methyl-ester-hydrochloride; NO: nitric oxide; Postop: postoperative; SD: Sprague Dawley.
Author Species Ghrelin type Eﬀective dose Methods Results Mechanism of action
Trudel L.,
[29]
Conscious
postop ileus
model
(SD male rats)
Human ghrelin-28
(IGBMC, France)
20μg/kg IV
given
immediately
after meal
Assessment of GE by
gastric retention of a
phenol red-marked
meal
Ghrelin reversed the
postop delayed GE
Trudel L.,
[42]
Conscious
postop ileus
model (female
mongrel dogs)
Ghrelin (IGBMC,
France)
(i) 100μg/kg
IV on day 2
(ii) 4μg/kg
IV on day 3
(iii) 20μg/kg
IV on day
4given after
meal
Assessment of GE by
acetaminophen
method
Ghrelin reversed the
postop delayed GE
De Winter B.,
[33]
Conscious LPS
septic ileus
model (Swiss
OFI mice)
(i) Rat ghrelin
(Tocris, UK)
(ii) GHRP-6
(Bachem, UK)
(i) Ghrelin:
100μg/kg
(ii) GHRP-
6:2 0a n d
100μg/kg
given IP 1h
prior to meal
Assessment of GE by
the gastric retention
of an Evans
blue-marked meal
Ghrelin and GHRP-6
accelerated GE in LPS
septic ileus mice
Poitras P.,
[31]
Conscious
postop ileus ±
morphine-
treated rat
model
(male SD rats)
Ghrelin receptor
agonist RC-1139
(Rejuvenon
Corp., USA)
2.5–10mg
/Kg IV given
immediately
after meal
Assessment of GE by
the retention of
99mTc-labelled meal
(i) RC-1139
accelerated GE
dose-dependently in
postop ileus rats
(ii) RC-1139 at
10mg/Kg accelerated
GE in postop ileus +
morphine-treated rats
Liu Y.,
[43]
Conscious
Cisplatin-
treated adult
male C57/6J
black mice
Rat ghrelin
(Bachem Ltd, UK)
1mg/Kg,IP
b.i.d
Assessment of gastric
emptying by the wet
weight of gastric
content
Ghrelin improved GE
Sallam H.,
[44]
Conscious
scald-burned
model
(SD male rats)
Ghrelin (Tocris,
USA)
2nmol/rat
given IP
20min before
meal
Assessment of GE by
gastric retention of a
phenol red-marked
meal
Ghrelin accelerated
GE; an eﬀect blocked
by pretreatment with
atropine
Ghrelin’s eﬀects on
gastric motility
involve the
cholinergic pathway
Venkova K.,
[45]
Conscious
postop ileus ±
morphine-
treated rat
model
(male SD rats)
Ghrelin receptor
agonist TZP-101
(Tranzyme
Pharma Canada)
0.1–1mg /Kg
(1ml) IV
given 1-2min
before meal
Assessment of GE by
the retention of
99mTc-labelled meal
TZP-101 accelerated
GE dose-dependently
in postop ileus rats ±
morphine
Qui et al.
[40]
Diabetic mouse
model (IP-
alloxan-treated
C57 mice)
Rat ghrelin
GHRP-6(Tocris,
UK)
50–200μg/Kg
given IP prior
to meal
Assessment of GE by
gastric retention of a
phenol red-marked
meal
Ghrelin and GHRP-6
at all doses
accelerated GE; an
eﬀect blocked by
atropine or L-NAME.
The eﬀects of Ghrelin
and GHRP-6 on GE
in diabetic
gastroparesis is
mediated via the
cholinergic pathways
Qui et al.
[41]
Diabetic guinea
pig model (IP-
STZ-treated)
Ghrelin
GHRP-6
20, 50 and
100μg/Kg
given IP prior
to meal
Assessment of GE by
gastric retention of a
phenol red-marked
meal
Ghrelin and GHRP-6
at all doses
accelerated GE; an
eﬀect blocked by
atropine.
The eﬀects of Ghrelin
and GHRP-6 on GE
in diabetic
gastroparesis are
mediated via the
cholinergic pathways6 International Journal of Peptides
Table 2: Continued.
Author Species Ghrelin type Eﬀective dose Methods Results Mechanism of action
Chen Y.,
[46]
LPS
endotoxemia
mouse model
(male ICR mice)
Rat ghrelin
(Global Peptide
Services, UDA)
20μg/Kg IP
given 15min
before meal
(i) Assessment of GE
by gastric retention of
a phenol red-marked
meal
(ii) Assessment of
plasma NO
production by
ﬂuorometry
(iii) Assessment of
iNos expression by
immunohisto-
chemistry
(i) Ghrelin had no
eﬀect on GE
(ii) Ghrelin
normalized
endotoxemia-induced
delayed GE
(iii) Ghrelin 20μg/Kg
reduced plasma NO
and iNOS expression
in the submucosa and
musculosa of the
stomach
Ghrelin’s eﬀect on
LPS-delayed GE are
mediated via the
down regulation of
NO
Zheng Q.,
[47]
Diabetic mouse
model (IP-
alloxan-treated
C57 mice)
GHRP-6 (Tocris,
UK)
200μg/kg
given IP prior
to meal
Assessment of GE by
gastric retention of a
phenol red-marked
meal
GHRP-6 accelerated
diabetic-induced
delayed GE; an eﬀect
blocked by
pretreatment with
atropine
GHRP-6 eﬀects on
gastric motility
involve the
cholinergic pathway
the NO and 5-HT pathways might be involved in the action
of ghrelin on intestinal interdigestive motility [58]. One year
later, Taniguchi et al. pinpointed the involvement of the 5-
HT4 receptor in the ghrelin’s action on intestinal MMCs
[7]. Recently, using a manometric method for simultaneous
assessment of gastro-duodenal motility, Tanaka et al. showed
that ghrelin induced MMCs in fed conscious freely moving
mice [22]. In dogs, however, ghrelin was shown to have no
eﬀect on intestinal MMCs [24].
Using a variety of techniques for the assessment of
intestinal transit, researchers proved that ghrelin or its
receptor agonist accelerated intestinal transit in rodents.
In 2002, Trudel et al. showed that IV ghrelin 20μg/kg
accelerated intestinal transit in rats [29]. This prokinetic
eﬀect of ghrelin on intestinal transit has been conﬁrmed
by several researchers using IV or IP ghrelin using the
same, or diﬀerent dose in rats [14, 15]o rm i c e[ 32, 46].
Ghrelin receptor agonists GHRP-6 or EX-1314 has also been
shown to have similar prokinetic results. EX-1314 did not
accelerate the intestinal transit in ghrelin receptor knockout
mice, conﬁrming the necessity of GHS-R activation for the
prokinetic action of ghrelin, in accordance to what has been
shown in the in vitro studies [15, 32, 36].
As for the colon, studies showed that to induce colon
propulsion in conscious, not anesthetized, rats, central
administrationofghrelinwasneeded.Although,ghrelinmay
exert an indirect eﬀect on the colon merely by triggering
upper GI MMCs, such possibility was not evidenced in the
literature. The lack of direct eﬀect of ghrelin on the colon
may possibly be due to the lack of ghrelin immunoreactive
cells and/or ghrelin receptors in the colon [1, 59, 60]. In
2002, Trudel et al. reported no eﬀect of IV ghrelin on
the colon of conscious rats [29]. In 2005, Tebbe et al.
showed that ghrelin, injected in the paraventricular nucleus
(PVN), stimulated colonic motility, dose dependently, in
freely moving conscious rats. This eﬀect involved central
activation of the PVN via the corticotrophin releasing factor
1( C R F 1) and the NPY1 receptors [61, 62]. In 2006, Shimizu
et al. reported that intrathecal ghrelin increased the colonic
propulsive function in anesthetized rats. Shimizu et al.
reported similar eﬀects with intrathecal, or IV, or IV infusion
of CP464709, a synthetic ghrelin receptor agonist which
exerted defecation in conscious rats that was dependent on
intact pelvic nerves [63]. In 2009, Charoenthongtrakul et
al. reported that oral EX-1314 increased fecal output in
conscious mice [32]. Shafton et al. tested a centrally acting
ghrelin receptor agonist, GSK894281 that was administrated
orally in conscious rats. They reported a dose-dependent
increase in the fecal output both acutely and after 8 days of
treatment [64].
5.3. In Human—Intestines of Healthy Subjects. Tack et al.
reported premature intestinal phase III contractions follow-
ing IV ghrelin in healthy volunteers. These contractions
were of gastric origin [35]. Although ghrelin, like motilin,
triggered intestinal MMCs in humans, but unlike motilin,
plasma ghrelin has not been reported to ﬂuctuate with
phase III, suggesting that motilin remains the main hormone
dominating interdigestive motility in man.
No studies were found on the eﬀects of ghrelin on colon
motility in healthy subjects.
6. Effects of GhrelinonIntestinal
MotilityinDisease
6.1. In Vitro—Intestinal Tissues in Disease. No studies were
found on the eﬀects of ghrelin on small intestinal tissues
obtained from diseased animal models.
However, ghrelin eﬀects on colitis rodent model were
reported. Recently, De Smet et al. showed that ghrelin
decreased the colonic inhibitory responses in healthy mice
and aggravated colitis in a dextran sodium sulfate (DDS)-
induced colitis mice model [65]. This is contradictory to sev-
eral studies in which ghrelin exerted an anti-inﬂammatoryInternational Journal of Peptides 7
Table 3: Prokinetic eﬀects of exogenous ghrelin in dyspeptic and/or gastroparetic patients. IDDM: insulin-dependent diabetes mellitus; GE:
gastric emptying; GHRP-6: ghrelin secretagogue receptor 6 (non-synthetic ghrelin receptor agonist); GHS-R: growth hormone secretagogue
receptor; h: hour; IV: intravenous; VAS: visual analogue scale.
Author Subjects Study design Ghrelin type Eﬀective dose Methods Results
Tack J.,
[48]
Six dyspeptic
patients
(5F, 1M)
Cross-sectional
Ghrelin
(Clinalfa,
Switzerland)
40μgI Vo v e rg i v e n
30min at the start of
the meal
(i) Assessment of GE
rates for solids and
liquids by the 14C
octanoic acid and
13C glycin breath tests
(ii) Assessment of the
intensity of 6
meal-related
symptoms
Ghrelin accelerated
GE for both liquids
a n ds o l i d s ,a sw e l la s
meal-related
symptom scores
Murray C.,
[49]
Ten IDDM
gastroparetic
patients
(5M, 5F)
Randomized,
double blinded,
cross-over
Synthetic
human
ghrelin
(Bachem,
UK)
5pmol/Kg/min IV
over 2 h
(i) Assessment of GE
rate by real time
ultrasonography
(ii) Assessment of the
symptoms by VAS
Ghrelin accelerated
GE rate, but had no
eﬀect on patients’
symptoms, despite
impaired cardiovagal
tone
Binn M.,
[50]
Six gastroparetic
patients (all F;
1 with truncal
vagotomy)
Cross-sectional
Synthetic
human
ghrelin
(Merck
Biosciences,
Switzerland)
20μg/ml IV over
1 minute
Assessment of GE by
C13-octanoic acid
breath test
Ghrelin accelerated
gastroparetic-induced
delayed GE, even
despite vagotomy
Bisschops R.,
[36]
Dyspeptic
patients with
delayed GE
(n = 6)
No information
(i) Ghrelin
(ii) GHRP-6
(Clinalfa,
Switzerland)
40μg IV infusion over
30min given 20min
at the start of the meal
(i) Assessment of GE
by 14Co c t a n o i ca c i d
and 13C glycin breath
test
(ii) Assessment of
meal-related
symptoms
(i) Ghrelin
accelerated GE of
liquids signiﬁcantly
and of solids
marginally
(ii) Ghrelin decreased
the cumulative
meal-related
symptom scores
Ejskjaer N.,
[51]
Diabetic
patients with
gastroparesis
(5M, 5F)
Randomized,
double-blind,
placebo-
controlled, single
dose, cross-over
TZP-101
(Tranzyme
Pharma)
80, 160, 320 and
600μg/Kg IV over
30min after meal
Assessment of GE by
scintigraphy
TZP-101 accelerated
GE of both liquid and
solid components of
the meal; no
signiﬁcant eﬀect on
symptoms
eﬀect in animal models of colitis [66, 67]. Further investiga-
tionisneededtoexploretheroleofghrelinincolitis-induced
dysmotility.
6.2. In Vivo—Intestinal Motility in Animal Model of Diseases.
Studies on the prokinetic eﬀects of exogenous ghrelin on
diseases intestines in vivo are summarized in Table 4. Similar
to its eﬀects on gastric emptying, ghrelin or its receptor ago-
nists have been reported to accelerate or normalize intestinal
transit in a variety of diseased animal models; these include
diabetic, postoperative, or morphine, or septic, or burn
induced ileus, and opiate-induced bowel disorder models.
(1) Diabetic model: Zheng et al. showed that ghrelin or
GHRP-6 increased intestinal transit; this eﬀect was mediated
via the cholinergic pathway [47]. (2) Postoperative ileus
and/or morphine-treated model: Venkova et al. tested another
ghrelin receptor agonist, TZP-101, that was also shown to
accelerate gastric emptying in postoperative ileus rodent
model whether or not it was aggravated by morphine [45].
(3) Septic model: controversial results have been reported
with IP ghrelin in LPS-induced septic ileus rodent models.
While De Winter et al. showed that ghrelin or GHRP-6
(100μg/kg) had no eﬀect in septic rats [33], Chen et al.
showed that ghrelin (20μg/kg) normalized the intestinal
transit in septic mice [46]. (4) Burn model: in 2007, we
have reported that ghrelin normalized the intestinal transit
in a 60% TSBA rat model; this eﬀect was mediated via the
cholinergic pathway [44]. (5) Opiate-induced bowel disorder
model: recently, Charoenthongtrakul et al. reported that EX-
1314 normalized opiate-induced delayed intestinal transit in
mice [32].
As for the colon, studies showed that IV administration
of ghrelin agonists (TZP-101, ipamorelin, or GHRP-6)
accelerated the colon transit in a postoperative ileus rat
model [68, 69], while IP ghrelin had no eﬀect on colon
motility in a scald burn rat model [44].8 International Journal of Peptides
Table 4: Prokinetic eﬀects of exogenous ghrelin on intestinal motility in vivo in disease. CT: colon transit; GHRP-6: ghrelin secretagogue
receptor 6 (non-synthetic ghrelin receptor agonist); h: hour; ICV: intracerebrovascular; iNOS: inducible nitric oxide synthase; IP:
intraperitoneal;IT:intestinaltransit;IV:intravenous;LPS:lipopolysaccharide;NO:nitricoxide;NPY:neuropeptideY;Postop:postoperative;
SC: subcutaneous; SD: Sprague Dawley.
Author Species Ghrelin type Eﬀective dose Methods Results Mechanism of action
De Winter B.,
[33]
Conscious
healthy and LPS
septic ileus
model (Swiss
OFI mice)
(i) Rat ghrelin
(Tocris, UK)
(ii) GHRP-6
(Bachem, UK)
(i) Ghrelin:
100μg/kg
(ii) GHRP-
6:20and
100μg/kg IP
1h prior to
meal
Assessment of IT by
the transit of an Evans
blue-marked meal
Ghrelin and GHRP-6,
at either dose] had no
prokinetic eﬀect on
IT in healthy or
diseased mice
Sallam H.,
[44]
Conscious
scald-burned
model
(SD male rats)
Ghrelin (Tocris,
USA)
2nmol/rat
given IP
20min
before meal
(ii) Assessment of IT
and CT by the transit
of a phenol red-
marked meal
Ghrelin accelerated
IT but had no
eﬀect on CT
Ghrelin’s eﬀects on
intestinal motility are
mediated via the
cholinergic pathway
Venkova K.,
[45]
Conscious
postop ileus ±
morphine-
treated rat
model
(male SD rats)
Ghrelin receptor
agonist TZP-101
(Tranzyme
Pharma Canada)
0.3–1mg /Kg
(1ml) IV
given 1-2min
before meal
Assessment of IT by
the transit of
99mTc-labelled meal
TZP-101 accelerated
IT dose-dependently
in postop ileus rats ±
morphine
Zheng Q.,
[47]
Conscious
diabetic mouse
model (IP-
alloxan-treated
C57 mice)
GHRP-6 (Tocris,
UK)
200μg/kg
given IP
prior to meal
Assessment of IT
and CT by the transit
of a phenol red-
marked meal
GHRP-6 accelerated
IT, but not CT; an
eﬀect blocked by
pretreatment with
atropine
GHRP-6 eﬀects on
intestinal motility
involve the
cholinergic pathway
Charoenth-
ongtrakul S.,
[32]
Conscious
opiate-induced
bowel disorder
mice model
(male lean
C57BL/6 mice)
Ghrelin receptor
agonist EX-1314
(Elixir Pharma-
ceuticals)
300μg/Kg
given PO
5min prior
to meal
Assessment of IT by
percentage of distance
of charcoal travelled/
t o t a ll e n g t ho fs m a l l
intestine
EX-1314 reversed
opiate-induced
delayed IT
Chen Y.,
[46]
LPS
endotoxemia
mouse model
(male ICR mice)
Rat ghrelin
(Global Peptide
Services, UDA)
20μg/Kg IP
given 15min
before meal
(i) Assessment of IT
by the of distance
charcoal travelled/
t o t a ll e n g t ho fs m a l l
intestine
(ii) Assessment of
plasma NO
production by
ﬂuorometry
(iii) Assessment of
iNos expression by
immunohisto-
chemistry
(i) Ghrelin
normalized
endotoxemia-
induced delayed IT
(ii) Ghrelin reduced
plasma NO and
iNOS expression in
the submucosa and
musculosa of the
duodenum
Ghrelin’s eﬀect on
LPS-delayed IT
transit is mediated via
the down regulation
of NO
Fraser G.,
[68]
Conscious
postop ileus rat
model
(male SD rats)
(i) Ghrelin
receptor agonist
TZP-101
(Tranzyme
Pharma, Canada)
0.3–1mg /Kg
(t.i.d) IV
given at
15min, 2
a n d4ha f t e r
surgery
Assessment of CT by
monitoring the time
of appearance and
weight of fecal pellet
output marked with
trypan blue dye
TZP-101 accelerated
CT dose-dependently
at 12 and 24 h after
surgeryInternational Journal of Peptides 9
Table 4: Continued.
Author Species Ghrelin type Eﬀective dose Methods Results Mechanism of
action
Venkova K.,
[69]
Conscious
postop ileus
rat model
(male SD rats)
(i) Ghrelin
receptor agonist
and selective
growth hormone
secretagogue
ipamorelin
(Albany Molecular
Research, Inc., NY)
(ii) GHRP-6
(Sigma-Aldrich,
MO)
(i) Ipamorelin
1mg/KgIVone
dose or 0.1
repetitive doses
(ii) GHRP-6
20μg/Kg IV
bolus given
after dosing of
4 doses/day at
3h intervals for
2d a y sa f t e r
surgery
Assessment of CT by
monitoring the time
of appearance and
weight of fecal pellet
output marked with
trypan blue dye
Ipamorelin and
GHRP-6 accelerated
CT 48h after surgery
6.3. In Human—Patients with Intestinal Motility Disorders.
No studies were found regarding the eﬀects of ghrelin in
patients with intestinal motility disorders.
7. Summary and Conclusion
In conscious animals, exogenous ghrelin was reported to
(1) induce gastric and intestinal MMCs in fed rodents,
but not in the canine; (2) exert controversial eﬀects on
gastric myoelectrical activity in rodents; (3) induce antral
contractions in dogs; (4) accelerate gastric emptying in
healthy, diabetic, postoperative, or morphine, or septic, or
burn-induced ileus, and cisplatin-induced dyspepsia animal
models; (5) accelerate intestinal transit in healthy, diabetic,
postoperative, or morphine, or septic, or burn induced
ileus, and opiate-induced bowel disorder rodent models; (6)
accelerate colonic transit in healthy rodents, when centrally
administrated.
Clinically, exogenous ghrelin was reported to (1) induce
gastric and intestinal MMCs in fasted healthy subjects; (2)
increase fundic tone in both fasted and fed healthy subjects;
(3) exert controversial eﬀects on gastric emptying and have
no eﬀect on postprandial symptoms in healthy subjects;
(4) accelerate gastric emptying in dyspeptic and/or gastro-
paretic patients and have debatable eﬀects on postprandial
symptoms in these patients. Luckily, the prokinetic eﬀects
of ghrelin in gastroparesis and/or dyspepsia patients were
independent of vagal involvement.
The prokinetic eﬀects of ghrelin on GI motility involve
the exclusive activation of the GHS-R 1a receptor, not the
motilin receptor, the enteric nervous system (speciﬁcally the
myenteric plexus), excitatory neurons involving 5-HT4 and
NO, capsaicin-sensitive aﬀerent neurons, tachykininergic
motor neurons, as well as intact vagal cholinergic neurons.
Oral ghrelin use is limited due to its instant inhibition
by the gastric acidic milieu; however, other routes for its
administration are possible. The emergence of IV ghrelin
agonists (e.g., synthetic peptide GHRP-6; synthetic non-
peptide capromorelin or ipamorelin) or ghrelin receptor
agonists (e.g., GSK894281, EX-1314, EX-1315, RC-1139,
TZP-101) are paving the way for possible uses in patient
treatment. Oral TZP-102 soon followed and has been tested
in healthy volunteers [70]. Other oral agonists include TZP-
102, EX-1314 and RC-1141.
In conclusion, the prokinetic face of ghrelin enables it to
serve as a strong tool in the clinical practice for the treatment
ofvariousGIdysmotility ailments.Theprokinetic properties
of ghrelin or its (receptor) agonists have the potential to
serve in the treatment of diabetic, neurogenic or idiopathic
gastroparesisandpossibly,chemotherapy-associateddyspep-
sia, postoperative, septic or post-burn ileus, opiate-induced
bowel dysfunction and chronic idiopathic constipation.
Further research is necessary to close the gap in knowledge
about the eﬀect of ghrelin on the human intestines in health
and disease.
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